Financial Results for the Third Quarter
of Fiscal Year Ending March 31, 2024 (FY2023)

from the beginning

Financial Results for the Third Quarter of Fiscal Year Ending March 31, 2024 (FY2023)

• Forward-Looking Statements and Use of Document

• Highlights

• P&L

• OP Variance Analysis (Q3): Further profitability improvement

• OP Variance Analysis (Q3 YTD): As planned in all areas

• Quarterly Gross Margin Trend

• Revenue by Region: Therapeutic devices strong in Americas. Asia drove high growth rate

• C&V: Americas and EU drove continuing strong sales; profit progress as planned

• TMCS: Increased sales and profit despite impact of Nutrition business divestiture,return to normal of thermometers

• TBCT: Strong blood center business drove large profit increase

• Annual Guidance Revision to Reflect FX Impact

• Upward Revision of Annual Guidance (FX Impact)

Reference

• C&V: Upward Revision of Annual Guidance (FX Impact)

• TMCS: Upward Revision of Annual Guidance (FX Impact)

• TBCT: Upward Revision of Annual Guidance (FX Impact)

• Revenue by Segment and Region

• Quarterly Revenue Trend

• Profitability Improvement Progress

• P&L (QoQ)

• SG&A (QoQ)

• SG&A (YoY)

• Adjusted Operating Profit: Adjustment Items

• CAPEX, Depreciation and Amortization, R&D Expenses

• Cash Flows (Q3 YTD)

• Cash Flows (Q3)

• FY23 Q3 YTD FX Impact Breakdown (Flow and Stock)

• Foreign Exchange Sensitivity

@